Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma.

Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, Yi Y, Shi JY, Shi GM, Ding ZB, Xiao YS, Zhao ZH, Zhou J, He XH, Fan J.

Cancer Res. 2012 Jul 15;72(14):3546-56. doi: 10.1158/0008-5472.CAN-11-4032. Epub 2012 Jun 18.

2.

The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.

Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E.

Cancer Res. 2008 Jun 15;68(12):4701-8. doi: 10.1158/0008-5472.CAN-08-0482. Retraction in: Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E. Cancer Res. 2011 Feb 1;71(3):1196.

3.

[Role of CXCL16/CXCR6 axis in the metastasis of human prostate cancer].

Zhou WH, Hu WD, Wu ZQ, Zheng XM, Wang BC.

Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):947-51. Chinese.

PMID:
20646641
4.

Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer.

Ha HK, Lee W, Park HJ, Lee SD, Lee JZ, Chung MK.

Mol Med Rep. 2011 May-Jun;4(3):419-24. doi: 10.3892/mmr.2011.446. Epub 2011 Mar 4.

PMID:
21468586
5.
6.

Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.

Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, Giese T, Felix K, Bergmann F, Giese NA, Friess H.

Int J Oncol. 2008 Aug;33(2):297-308.

PMID:
18636150
7.

CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.

Lu Y, Wang J, Xu Y, Koch AE, Cai Z, Chen X, Galson DL, Taichman RS, Zhang J.

Mol Cancer Res. 2008 Apr;6(4):546-54. doi: 10.1158/1541-7786.MCR-07-0277. Epub 2008 Mar 14.

8.

Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer.

Huang Y, Zhang J, Cui ZM, Zhao J, Zheng Y.

Chin J Cancer. 2013 May;32(5):289-96. doi: 10.5732/cjc.012.10063. Epub 2012 Sep 10.

9.

CXCL16 and CXCR6 are coexpressed in human lung cancer in vivo and mediate the invasion of lung cancer cell lines in vitro.

Hu W, Liu Y, Zhou W, Si L, Ren L.

PLoS One. 2014 Jun 4;9(6):e99056. doi: 10.1371/journal.pone.0099056. eCollection 2014.

10.

CXCR6: the role of environment in tumor progression. Challenges for therapy.

La Porta CA.

Stem Cell Rev. 2012 Dec;8(4):1282-5. doi: 10.1007/s12015-012-9383-6. Review.

PMID:
22678828
11.

CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells.

Hu W, Zhen X, Xiong B, Wang B, Zhang W, Zhou W.

Cancer Sci. 2008 Jul;99(7):1362-9. doi: 10.1111/j.1349-7006.2008.00833.x. Epub 2008 Apr 29. Erratum in: Cancer Sci. 2008 Dec;99(12):2548.

12.

Involvement of Escherichia coli in pathogenesis of xanthogranulomatous cholecystitis with scavenger receptor class A and CXCL16-CXCR6 interaction.

Sawada S, Harada K, Isse K, Sato Y, Sasaki M, Kaizaki Y, Nakanuma Y.

Pathol Int. 2007 Oct;57(10):652-63.

PMID:
17803654
13.

The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.

Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA, Pikarsky E, Karin M, Farber JM.

PLoS One. 2009 Aug 19;4(8):e6695. doi: 10.1371/journal.pone.0006695.

14.

Expression and localization of CXCL16 and CXCR6 in ovarian endometriotic tissues.

Manabe S, Iwase A, Goto M, Kobayashi H, Takikawa S, Nagatomo Y, Nakahara T, Bayasula, Nakamura T, Hirokawa W, Kikkawa F.

Arch Gynecol Obstet. 2011 Dec;284(6):1567-72. doi: 10.1007/s00404-011-2002-y. Epub 2011 Jul 20.

PMID:
21773780
15.

Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells.

Tabata S, Kadowaki N, Kitawaki T, Shimaoka T, Yonehara S, Yoshie O, Uchiyama T.

J Leukoc Biol. 2005 May;77(5):777-86. Epub 2005 Feb 9.

PMID:
15703197
16.

Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients.

Matsushita K, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K, Inoue Y, Kusunoki M.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S518-27. doi: 10.1245/s10434-011-1993-8. Epub 2011 Aug 16.

PMID:
21845497
17.

The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer.

Richardsen E, Ness N, Melbø-Jørgensen C, Johannesen C, Grindstad T, Nordbakken C, Al-Saad S, Andersen S, Dønnem T, Nordby Y, Bremnes RM, Busund LT.

Am J Pathol. 2015 Oct;185(10):2722-30. doi: 10.1016/j.ajpath.2015.06.013. Epub 2015 Aug 10.

PMID:
26272362
18.

CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms.

Xiao G, Wang X, Wang J, Zu L, Cheng G, Hao M, Sun X, Xue Y, Lu J, Wang J.

Oncotarget. 2015 Jun 10;6(16):14165-78.

19.

Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis.

Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N.

Arthritis Rheum. 2005 Oct;52(10):3004-14.

20.

CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering.

Singh R, Kapur N, Mir H, Singh N, Lillard JW Jr, Singh S.

Oncotarget. 2016 Feb 9;7(6):7343-53. doi: 10.18632/oncotarget.6944.

Supplemental Content

Support Center